New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 27, 2014
09:09 EDTKERXKeryx could benefit from House bill, says JMP Securities
After reviewing language in the House doc fix bill, JMP Securities indicates that reimbursement for Keryx's Zerenex drug may not be cut 37.5% beginning in 2016, as the firm had previously expected. The bill indicates that the reduction may be delayed until 2024, according t o the firm which keeps an Outperform rating on the shares.
News For KERX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 21, 2015
19:55 EDTKERXKeryx 9.17M share Secondary priced at $12.00
The deal size was raised to 9.17M shares from 7.2M shares. JPMorgan acted as sole book running manager for the offering.
January 20, 2015
18:30 EDTKERXOn The Fly: After Hours Movers
Subscribe for More Information
16:06 EDTKERXKeryx files to sell $100M in common stock
J.P. Morgan is acting as the sole book-running manager in the offering. Keryx intends to use the net proceeds from the sale of its common stock to fund the ongoing commercialization and development of Auryxia in the US, pre-commercial activities in Europe, to potentially in-license, acquire and develop additional drug candidates, and other general corporate purposes.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use